Karissa Johnston Selected Research

rimegepant sulfate

1/2022	Monthly migraine days, tablet utilization, and quality of life associated with Rimegepant - post hoc results from an open label safety study (BHV3000-201).
1/2022	Comparative efficacy and safety of rimegepant, ubrogepant, and lasmiditan for acute treatment of migraine: a network meta-analysis.
1/2021	Matching-adjusted indirect comparisons of oral rimegepant versus placebo, erenumab, and galcanezumab examining monthly migraine days and health-related quality of life in the treatment of migraine.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Karissa Johnston Research Topics

Disease

5	Migraine Disorders (Migraine) 06/2022 - 01/2021
3	Urinary Tract Infections (Urinary Tract Infection) 01/2019 - 10/2018
3	Infections 10/2018 - 07/2008
2	Atypical Hemolytic Uremic Syndrome 01/2022 - 12/2020
2	Hemophilia A (Haemophilia) 01/2021 - 01/2017
2	Overactive Urinary Bladder (Overactive Bladder) 11/2020 - 01/2019
2	Type 2 Diabetes Mellitus (MODY) 02/2020 - 10/2018
2	HIV Infections (HIV Infection) 01/2010 - 07/2008
1	Pain (Aches) 01/2022
1	Dizziness (Lightheadedness) 01/2022
1	Sleepiness 01/2022
1	Headache (Headaches) 11/2021
1	Secondary Headache Disorders 11/2021
1	Asthma (Bronchial Asthma) 10/2021
1	Constipation 11/2020
1	Hypoglycemia (Reactive Hypoglycemia) 02/2020
1	Acute Kidney Injury (Acute Renal Failure) 01/2019
1	Diabetic Ketoacidosis (Ketoacidosis, Diabetic) 01/2019
1	Bone Fractures (Bone Fracture) 01/2019
1	Hemorrhage 01/2017
1	Joint Diseases (Joint Disease) 01/2017
1	Fatigue 01/2017
1	Liver Cirrhosis (Hepatic Cirrhosis) 07/2015
1	Thyroid Neoplasms (Thyroid Cancer) 01/2015
1	Acquired Immunodeficiency Syndrome (AIDS) 01/2009
1	Neoplasms (Cancer) 09/2008
1	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 09/2008

Drug/Important Bio-Agent (IBA)

3	rimegepant sulfateIBA 01/2022 - 01/2021
2	Calcitonin Gene-Related PeptideIBA 06/2022 - 01/2021
2	ravulizumabIBA 01/2022 - 12/2020
2	eculizumab FDA Link 01/2022 - 12/2020
2	mirabegronIBA 11/2020 - 01/2019
2	Muscarinic AntagonistsIBA 11/2020 - 01/2019
2	Sodium-Glucose Transporter 2 InhibitorsIBA 01/2019 - 10/2018
1	Monoclonal AntibodiesIBA 06/2022
1	TabletsIBA 01/2022
1	lasmiditanIBA 01/2022
1	ubrogepantIBA 01/2022
1	Tryptamines (Triptans)IBA 11/2021
1	Analgesics (Analgesic Drugs)IBA 11/2021
1	Opioid Analgesics (Opioids)IBA 11/2021
1	benralizumabIBA 10/2021
1	galcanezumabIBA 01/2021
1	erenumabIBA 01/2021
1	Factor VIII (Coagulation Factor VIII)IBA 01/2021
1	emicizumabIBA 01/2021
1	Calcitonin Gene-Related Peptide Receptor AntagonistsIBA 01/2021
1	Cholinergic Antagonists (Anticholinergics)IBA 11/2020
1	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 02/2020
1	Hypoglycemic Agents (Hypoglycemics)IBA 02/2020
1	Pharmaceutical PreparationsIBA 02/2020
1	Type A Botulinum Toxins (Botox)FDA Link 01/2019
1	Glucose (Dextrose)FDA LinkGeneric 10/2018
1	SodiumIBA 10/2018
1	A-factor (Streptomyces)IBA 01/2017
1	IodineIBA 01/2015
1	Imatinib Mesylate (Gleevec)FDA Link 09/2008

Therapy/Procedure

5	Therapeutics 01/2021 - 01/2017
3	Highly Active Antiretroviral Therapy (HAART) 01/2010 - 07/2008
1	Duration of Therapy 01/2022
1	Surgical Amputation (Amputations) 01/2019
1	Replacement Arthroplasty 01/2017
1	Aftercare (After-Treatment) 01/2017
1	Liver Transplantation 07/2015